The Financial Mail on Sunday's Midas column recommended shares of Impact Healthcare, as 'a long-term buy', touting the company's long-term growth prospects, dividend yield of over 5. 0% and management's attention to detail which they surmised was paying off.
Elon Musk has begun discussions with possible partners for a bid on Twitter after the iconic social media outfit put in place a so-called 'poison pill' in an attempt to thwart a mooted £33bn takeover. That stratagem was preceded by Twitter's rejection of an offer from Musk last Friday worth $54. 20 a share. The pill would be activated should Musk take his own stake over the 15% threshold. - Sunday Times.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.
The value of investments can fall and you may get back less than you invested.